Liu Ye 4
4 · EyePoint Pharmaceuticals, Inc. · Filed May 31, 2023
Insider Transaction Report
Form 4
Liu Ye
Director
Transactions
- Sale
Common Stock, $0.001 par value
2023-05-30$6.00/sh−1$6→ 3,010,721 total(indirect: Ocumension Therapeutics)
Footnotes (2)
- [F1]Sale of one share to test new broker
- [F2]The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.